BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Precision Medical Sciences is a pioneering open-access journal, launched in 2020 and published by the esteemed WILEY, dedicated to disseminating cutting-edge research and advancements in the field of precision medicine. With the ISSN 2642-2514, this journal serves as a critical platform for researchers, healthcare professionals, and students to explore innovative approaches that personalize medical treatment, optimize patient outcomes, and advance the understanding of patient variability in response to therapies. The adoption of open-access policies ensures that groundbreaking findings are readily available to the global scientific community, fostering collaboration and knowledge sharing among experts. Although currently lacking an H-index, the journal aspires to establish a robust reputation in the medical literature landscape, supporting the ongoing evolution of tailored healthcare solutions. Researchers are encouraged to contribute their findings to enhance the journal’s commitment to excellence in precision medical sciences.

Asia-Pacific Journal of Clinical Oncology is an essential publication within the field of medical oncology, dedicated to advancing the understanding and treatment of cancer through rigorous research and innovative clinical practices. Published by WILEY, this journal has established itself as a significant resource for researchers, healthcare professionals, and students interested in the latest findings across the Asia-Pacific region and beyond. With a respectable impact factor and categorized within the Q2 and Q3 quartiles of Medicine (miscellaneous) and Oncology respectively, the journal aims to disseminate knowledge on diverse aspects of clinical oncology, promoting the improvement of patient care and treatment outcomes. The Asia-Pacific Journal of Clinical Oncology, operating from the United Kingdom, invites contributions that highlight significant findings and advancements in oncology, making it a crucial platform for collaboration and knowledge sharing in this vital field of medicine.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.